INDIAN FACE
INDIAN EQUITY BENCHMARK
Benchmark indices ended flat
after hitting record highs in the early trade on December 20. At
close, the Sensex was up 7.62 points or 0.02% at 41681.54, and
the Nifty was up 12.10 points or 0.10% at 12271.80. About 1244
shares have advanced, 1232 shares declined, and 169 shares are
unchanged. Nestle India, Titan Company, Tata Steel, UPL and
SBI were among major gainers on the Nifty, while losers were
Vedanta, Kotak Mahindra Bank, Tata Motors, ITC and Eicher
Motors.
Asian Market- Asian markets finished mixed as of the most recent closing prices. The Hang Seng gained 0.25%, while the Shanghai Composite led the Nikkei 225 lower. They fell 0.40% and 0.20% respectively
U.S. Market – North and South American markets finished mixed as of the most recent closing prices. The Bovespa gained 0.71% and the S&P 500 rose 0.45%. The IPC lost 1.01%.
European markets- European markets are higher today with shares in Germany leading the region. The DAX is up 0.33% while France's CAC 40 is up 0.26% and London's FTSE 100 is up 0.19%.
NIFTY SPOT
MARKET TALKS
Cadila Healthcare informs regarding USFDA inspection at Ahmedabad facility
Cadila Healthcare informed the exchanges that the USFDA inspected the company’s topical manufacturing facility located in Ahmedabad from 16th to 20th December, 2019. At the end of the inspection, no observation (483) is issued. Cadila Healthcare Ltd is currently trading at Rs265.65 up by Rs4.1 or 1.57% from its previous closing of Rs261.55 on the BSE. The scrip opened at Rs260.90 and has touched a high and low of Rs267.65 and Rs260.30 respectively. So far 12, 49,963 (NSE+BSE) shares were traded on the counter.
Lupin gets approval for Betamethasone Dipropionate Ointment USP
Pharma major Lupin Limited (Lupin) announced today that it has received approval for its Betamethasone Dipropionate Ointment USP (Augmented), 0.05%, from the United States Food and Drug Administration (USFDA), to market a generic equivalent of Diprolene Ointment, 0.05%, of Merck Sharp and Dohme Corp. The product will be manufactured at Lupin’s Pithampur (Unit 3) facility, India. Betamethasone Dipropionate Ointment USP (Augmented), 0.05%, is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years of age and older.
Shell, Reliance and ONGC JV transfer Panna-Mukta fields back to ONGC
After 25 years of operating the Panna-Mukta oil and gas fields, the Panna-Mukta and Tapti (PMT) Joint Venture partners will be handing over the Panna-Mukta oil and gas fields back to the Government of India’s nominee.
Dilip Buildcon gets an appointment date from NHAI for Karnataka project
Dilip Buildcon Ltd. informed the exchanges that DBL Nidagatta Mysore Highways Private Limited, wholly owned subsidiary of the company, has received the appointed date, i.e., December 10, 2019 by the National Highway Authority of India (NHAI). The project involves six-laning from Nidagatta Mysore Section from 74.200 to135.304 km of NH-275 in the State of Karnataka to be executed on Hybrid Annuity Mode. The cost of the project is Rs2283.50cr for a period of 30 months. Operation period is for a period of 15 years from COD. Dilip Buildcon Ltd is currently trading at Rs406.85 down by Rs5.85 or 1.42% from its previous closing of Rs412.70 on the BSE.
NAME OF THE STOCK : ICICIGI
DATE : 23/12/2019
SEGMENT : CASH
CHART TYPE : Candlestick
EXCHANGE : NSE
TECHNICAL INDICATORS USED : VOLUME.MACD, RSI.
INVESTMENT ADVICE:
CALL CS CALL: BUY ICICIGI CASH NR CMP 1409 TGT 1450 SL 1380
RATIONALE FOR ARRIVING INVESTMENT ADVICE :
THE STOCK TECHINCALLY IS UP ,TAKING SUPPORT OF VOLUME.RESISTANCE IS BROKEN TODAY WITH HEAVY VOLUME.AS WELL AS A POSSIBILITY OF UPWARD MOVEMENT IS THERE.
OTHER REASON IF ANY: SHOWING STRENGTHS IN INTRADAY CHARTS AS WELL
DISCLAIMER
The information and views in this report & all the service we provide are believed to be reliable, but we do not accept any responsibility for errors of fact or opinion. Investors have the right to choose the product/s that suits them the most. Sincere efforts have been made to present the right investment perspective. The information contained herein is based on analysis and upon sources that we consider reliable. This material is for personal information and based upon it & takes no responsibility. The information given herein should be treated as the only factor while making investment decisions. The report does not provide individually tailor-made investment advice. My research recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. CapitalStars shall not be responsible for any transaction conducted based on the information given in this report, which is in violation of rules and regulations of regulators. The price projections shown are not necessarily indicative of future price performance. The information herein, together with all estimates and forecasts, can change without notice. It is understood that anyone who is browsing through the site has done so at his free will and does not read any views expressed as a recommendation for which either the site or its owners or anyone can be held responsible for. Investment & Trading in Securities Markets is always subjected to market risk.
CLICK HERE FOR GETTING DETAILS & JOIN OUR BEST ADVISORY -
Visit our Link : https://www.capitalstars.com/free-trial
CAPITALSTARS CALL US : 9977499927
Derivatives Tips , Intraday Stock Tips , FreeTrading Tips, Sebi Registered advisory
0 Comments